vs
Side-by-side financial comparison of RYTHM, Inc. (RYM) and UPEXI, INC. (UPXI). Click either name above to swap in a different company.
RYTHM, Inc. is the larger business by last-quarter revenue ($10.7M vs $8.1M, roughly 1.3× UPEXI, INC.). RYTHM, Inc. runs the higher net margin — -127.6% vs -2222.1%, a 2094.5% gap on every dollar of revenue. On growth, RYTHM, Inc. posted the faster year-over-year revenue change (242.0% vs 101.0%). Over the past eight quarters, RYTHM, Inc.'s revenue compounded faster (102.6% CAGR vs 24.2%).
RYTHM, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing innovative therapies for rare genetic endocrine and metabolic disorders with high unmet medical needs. It primarily operates in the U.S. market, targeting pediatric and adult patient segments that lack standard effective treatment options.
RYM vs UPXI — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $10.7M | $8.1M |
| Net Profit | $-13.6M | $-178.9M |
| Gross Margin | 75.5% | 83.3% |
| Operating Margin | -121.5% | -2177.9% |
| Net Margin | -127.6% | -2222.1% |
| Revenue YoY | 242.0% | 101.0% |
| Net Profit YoY | 44.1% | -13649.6% |
| EPS (diluted) | $-6.78 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $10.7M | $8.1M | ||
| Q3 25 | $4.0M | $9.2M | ||
| Q2 25 | $2.0M | $4.3M | ||
| Q1 25 | $538.0K | $3.2M | ||
| Q4 24 | $-7.5M | $4.0M | ||
| Q3 24 | $1.9M | $4.4M | ||
| Q2 24 | $3.0M | $5.0M | ||
| Q1 24 | $2.6M | $5.2M |
| Q4 25 | $-13.6M | $-178.9M | ||
| Q3 25 | $-10.7M | $66.7M | ||
| Q2 25 | $-7.4M | $-6.9M | ||
| Q1 25 | $-1.6M | $-3.8M | ||
| Q4 24 | $-24.4M | $-1.3M | ||
| Q3 24 | $-18.7M | $-1.6M | ||
| Q2 24 | $-3.0M | $-15.7M | ||
| Q1 24 | $4.2M | $-4.1M |
| Q4 25 | 75.5% | 83.3% | ||
| Q3 25 | 34.0% | 89.6% | ||
| Q2 25 | 33.4% | 79.4% | ||
| Q1 25 | 16.7% | 49.3% | ||
| Q4 24 | — | 74.3% | ||
| Q3 24 | 11.6% | 67.3% | ||
| Q2 24 | 37.6% | 31.0% | ||
| Q1 24 | 6.4% | 24.3% |
| Q4 25 | -121.5% | -2177.9% | ||
| Q3 25 | -219.8% | — | ||
| Q2 25 | -332.9% | -151.7% | ||
| Q1 25 | -687.9% | -113.5% | ||
| Q4 24 | — | -26.8% | ||
| Q3 24 | -63.1% | -30.6% | ||
| Q2 24 | -28.5% | -265.2% | ||
| Q1 24 | 13.6% | -96.5% |
| Q4 25 | -127.6% | -2222.1% | ||
| Q3 25 | -263.8% | 722.4% | ||
| Q2 25 | -360.4% | -161.5% | ||
| Q1 25 | -302.2% | -121.2% | ||
| Q4 24 | 324.4% | -32.5% | ||
| Q3 24 | -964.4% | -37.3% | ||
| Q2 24 | -99.3% | -312.4% | ||
| Q1 24 | 163.0% | -78.9% |
| Q4 25 | $-6.78 | — | ||
| Q3 25 | $-5.33 | $0.76 | ||
| Q2 25 | $-3.74 | $0.83 | ||
| Q1 25 | $-0.83 | $-2.87 | ||
| Q4 24 | $-24.26 | $-1.24 | ||
| Q3 24 | $-17.28 | $1.55 | ||
| Q2 24 | $-3.16 | $-15.66 | ||
| Q1 24 | $3.78 | $-4.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $32.2M | — |
| Total DebtLower is stronger | $80.6M | — |
| Stockholders' EquityBook value | $13.0M | $48.7M |
| Total Assets | $106.7M | $271.1M |
| Debt / EquityLower = less leverage | 6.19× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.2M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $41.0M | — | ||
| Q1 25 | $24.4M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $267.0K | — | ||
| Q2 24 | $57.0K | — | ||
| Q1 24 | $99.0K | — |
| Q4 25 | $80.6M | — | ||
| Q3 25 | $90.6M | — | ||
| Q2 25 | $40.6M | — | ||
| Q1 25 | $10.6M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $6.2M | — | ||
| Q2 24 | $4.6M | — | ||
| Q1 24 | — | — |
| Q4 25 | $13.0M | $48.7M | ||
| Q3 25 | $11.7M | $210.8M | ||
| Q2 25 | $21.0M | $90.1M | ||
| Q1 25 | $26.8M | $1.9M | ||
| Q4 24 | $28.1M | $3.8M | ||
| Q3 24 | $5.5M | $5.0M | ||
| Q2 24 | $8.5M | $6.5M | ||
| Q1 24 | $-5.5M | $22.1M |
| Q4 25 | $106.7M | $271.1M | ||
| Q3 25 | $115.2M | $419.7M | ||
| Q2 25 | $69.5M | $123.8M | ||
| Q1 25 | $45.6M | $15.1M | ||
| Q4 24 | $54.0M | $17.5M | ||
| Q3 24 | $39.0M | $18.6M | ||
| Q2 24 | $39.4M | $23.5M | ||
| Q1 24 | $40.6M | $56.5M |
| Q4 25 | 6.19× | — | ||
| Q3 25 | 7.73× | — | ||
| Q2 25 | 1.94× | — | ||
| Q1 25 | 0.40× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.13× | — | ||
| Q2 24 | 0.54× | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-3.0M | $-2.7M |
| Free Cash FlowOCF − Capex | — | $-2.7M |
| FCF MarginFCF / Revenue | — | -33.5% |
| Capex IntensityCapex / Revenue | — | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-22.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-3.0M | $-2.7M | ||
| Q3 25 | $-5.4M | $-9.8M | ||
| Q2 25 | $-8.4M | $-8.4M | ||
| Q1 25 | $-6.7M | $-778.7K | ||
| Q4 24 | $-5.3M | $-1.4M | ||
| Q3 24 | $-1.4M | $-2.0M | ||
| Q2 24 | $-1.8M | $-101.4K | ||
| Q1 24 | $-3.0M | $783.5K |
| Q4 25 | — | $-2.7M | ||
| Q3 25 | — | $-9.8M | ||
| Q2 25 | — | $-8.8M | ||
| Q1 25 | — | $-809.3K | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-2.1M | ||
| Q2 24 | $-1.8M | $-1.0M | ||
| Q1 24 | $-3.0M | $600.9K |
| Q4 25 | — | -33.5% | ||
| Q3 25 | — | -106.0% | ||
| Q2 25 | — | -205.4% | ||
| Q1 25 | — | -25.6% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -49.2% | ||
| Q2 24 | -61.2% | -20.5% | ||
| Q1 24 | -115.1% | 11.5% |
| Q4 25 | — | 0.2% | ||
| Q3 25 | — | 0.2% | ||
| Q2 25 | — | 9.0% | ||
| Q1 25 | — | 1.0% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 3.8% | ||
| Q2 24 | 0.1% | 18.5% | ||
| Q1 24 | 0.1% | 3.5% |
| Q4 25 | — | — | ||
| Q3 25 | — | -0.15× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -0.71× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
RYM
| Nonlicensing Revenue | $9.5M | 89% |
| Cultivation Business Discontinued Operations | $1.2M | 11% |
UPXI
Segment breakdown not available.
